|
Pluristem Therapeutics Announces $1.6 Million Securities
Offering
Wednesday August 6, 8:00 am ET |
|
|
NEW YORK--(BUSINESS
WIRE)--Pluristem Therapeutics Inc. (Nasdaq:PSTI)
(DAX:PJT), a bio-therapeutics company dedicated
to the commercialization of non-personalized
(allogeneic) cell therapy products for a variety
of degenerative, ischemic and autoimmune
indications, today announced it has entered into
definitive agreements to sell common stock and
warrants to selected institutional investors for
aggregate gross proceeds of $1,600,000. The
offering is made pursuant to the Form S-3 shelf
registration statement that was filed by
Pluristem with the Securities and Exchange
Commission (the “SEC”)
and declared effective by the SEC on July 1,
2008. The offering is expected to close on or
about August 8, 2008, subject to the
satisfaction of customary closing conditions.
Pluristem intends to use the net proceeds from
the offering for its expected clinical trial,
working capital and general corporate purposes.
|
Source:
Pluristem Therapeutics Inc. |
|
|
|
|
|
|
The securities sold in the
offering were 1,391,304 shares of common stock
at a price of $1.15 per share and five-year
warrants to purchase 695,652 shares of common
stock at an exercise price of $1.90 per share.
Mr. Zami Aberman, Pluristem’s
President and CEO, commented:
“We will use these funds to move forward
our planned clinical trials in the USA and
Europe for our PLX-PAD, intended to improve the
quality of life of millions of people suffering
from peripheral artery disease.”
Rodman & Renshaw, LLC, a wholly
owned subsidiary of Rodman & Renshaw Capital
Group, Inc. (Nasdaq:RODM),
acted as the exclusive placement agent for the
offering.
This press release shall not
constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale
of these securities in any jurisdiction in which
such offer, solicitation or sale would be
unlawful. Any offer will be made only by means
of a prospectus, including a prospectus
supplement, forming a part of the effective
registration statement. Copies of the prospectus
supplement together with the accompanying
prospectus can be obtained at the SEC’s
website at
http://www.sec.gov or from Rodman & Renshaw,
LLC, 1251 Avenue of the Americas, 20th Floor,
New York, NY, 10020.
About Pluristem Therapeutics
Inc.
Pluristem Therapeutics Inc. is a
bio-therapeutics company dedicated to the
commercialization of non-personalized
(allogeneic) cell therapy products for the
treatment of several severe degenerative,
ischemic and autoimmune disorders. The Company
is developing a pipeline of products, stored
ready-to-use, that are derived from human
placenta, a non-controversial, non-embryonic,
adult stem cell source.
These placental mesenchymal
stromal cells (MSCs) are expanded in the
Company's proprietary PluriXTM
3D bioreactor, which imitates the natural
microstructure of bone marrow and does not
require supplemental growth factors or other
exogenous materials. Pluristem believes that the
resultant PLX (PLacental eXpanded) cells are
multi-potent and able to differentiate into a
variety of cell types. Recent evidence also
suggests their efficacy may be related to the
secretion of cytokines or other potent immune
modulators. Furthermore, PLX cells are immune
privileged and have immunomodulatory properties,
thus protecting the recipient from immunological
reactions that often accompany transplantations.
Pluristem's first product in
development, PLX-PAD, is intended to improve the
quality of life of millions of people suffering
from peripheral artery disease (PAD). The
Company's products in development also include
PLX-BMT, targeting the global shortfall of
matched tissue for bone marrow transplantation
(BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in
umbilical cord blood; PLX-STROKE, targeting
ischemic stroke; PLX-MS, targeting Multiple
Sclerosis; and PLX-IBD, targeting Inflammatory
Bowel Disease (IBD), which includes Crohn’s
disease and Ulcerative Colitis.
Pluristem has offices in the USA
with research and manufacturing facilities in
Israel.
See our product animation on
YouTube:
http://www.youtube.com/watch?v=OFhWXyJT6Us
Safe Harbor Statement
This press release contains
forward-looking statements within the meaning of
the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and
federal securities laws. For example, when we
discuss our intentions regarding the use of
funds raised, we are using forward-looking
statements. These forward-looking statements are
based on the current expectations of the
management of Pluristem only, and are subject to
a number of factors and uncertainties that could
cause actual results to differ materially from
those described in the forward-looking
statements. The following factors, among others,
could cause actual results to differ materially
from those described in the forward-looking
statements: changes in technology and market
requirements; our technology may not be
validated as we progress further and our methods
may not be accepted by the scientific community;
we may be unable to retain or attract key
employees whose knowledge is essential to the
development of our products; unforeseen
scientific difficulties may develop with our
process; results in the laboratory may not
translate to equally good results in real
surgical settings; our patents may not be
sufficient; our products may harm recipients;
changes in legislation; inability to timely
develop and introduce new technologies, products
and applications; loss of market share and
pressure on pricing resulting from competition,
which could cause the actual results or
performance of Pluristem to differ materially
from those contemplated in such forward-looking
statements. Except as otherwise required by law,
Pluristem undertakes no obligation to publicly
release any revisions to these forward-looking
statements to reflect events or circumstances
after the date hereof or to reflect the
occurrence of unanticipated events. For a more
detailed description of the risk and
uncertainties affecting Pluristem, reference is
made to Pluristem's reports filed from time to
time with the Securities and Exchange
Commission.
For more information visit our
website at
www.pluristem.com, the content of which is
not part of this press release.
MULTIMEDIA AVAILABLE:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5749665
Contact:
Pluristem Therapeutics Inc.
William Prather RPh, MD, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
Source: Pluristem Therapeutics Inc.
|
|
|
|